Citric acid
/ /, Clenpiq, G, Idkit:hp, Phexxi, Renacidin (citric acid) is a small molecule pharmaceutical. Citric acid was first approved as Irrigating solution g in plastic container on 1982-06-22. It is used to treat renal tubular acidosis and urination disorders in the USA. It is known to target polycystin-2-like protein 1 and transient receptor potential cation channel subfamily V member 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Combinations
Clenpiq, Phexxi, Picosulfate, magnesium oxide anhydrous citric acid, Renacidin (discontinued: Irrigating solution g, Prepopik, Urologic g)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Citric acid
+
Magnesium oxide
+
Sodium carbonate
Citric acid
+
Magnesium oxide
+
Sodium picosulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CLENPIQ | Ferring Pharmaceuticals | N-209589 RX | 2017-11-28 | 1 products, RLD, RS |
Show 1 discontinued
Citric acid
+
Lactic acid
+
Potassium bitartrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PHEXXI | Evofem Biosciences | N-208352 RX | 2020-05-22 | 1 products, RLD, RS |
Citric acid
+
Gluconolactone
+
Magnesium carbonate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RENACIDIN | United Guardian | N-019481 RX | 1990-10-02 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 2080 dentistry night fresh | OTC monograph final | 2017-02-03 |
| abstral | New Drug Application | 2014-11-30 |
| acd | ANDA | 2025-01-22 |
| acd blood-pack units (pl 146 plastic) | New Drug Application | 2022-04-27 |
| acd-a | New Drug Application | 2022-11-01 |
| additive formula 3 | New Drug Application | 2025-01-24 |
| adea gargle | unapproved drug other | 2018-03-26 |
| adsol red cell preservation | New Drug Application | 2022-11-22 |
| adsol red cell preservation solution system in plastic container (pl 146 plastic) | New Drug Application | 2022-11-02 |
| adsol red cell preservation system in plastic container (pl 146 plastic) | New Drug Application | 2019-05-08 |
Show 216 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| urination disorders | — | D014555 | — |
| renal tubular acidosis | — | D000141 | N25.89 |
| dermatitis | — | D003872 | L30.9 |
| facial dermatoses | — | D005148 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
CITRIC ACID / LACTIC ACID / POTASSIUM BITARTRATE, PHEXXI, EVOFEM INC | |||
| 2023-05-22 | NP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Citric Acid / Magnesium Oxide / Sodium Picosulfate, Clenpiq, Ferring Pharms Inc | |||
| 9827231 | 2034-06-26 | DP | U-2162 |
| 10624879 | 2034-06-23 | DP | |
| 11191753 | 2034-06-23 | U-3261 | |
| Citric Acid / Lactic Acid / Potassium Bitartrate, Phexxi, Evofem Inc | |||
| 10568855 | 2033-03-15 | U-1 | |
| 11337989 | 2033-03-15 | U-1 | |
| 11439610 | 2033-03-15 | DS, DP | |
| 6706276 | 2023-09-06 | DP | |
| Citric Acid / Magnesium Oxide / Sodium Picosulfate, Prepopik, Ferring Pharms Inc | |||
| 8450338 | 2028-10-10 | DP | |
| 8481083 | 2028-10-10 | DP | |
HCPCS
No data
Clinical
Clinical Trials
2224 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 9 | 38 | 53 | 1 | 14 | 113 |
| Infertility | D007246 | EFO_0000545 | — | 10 | 18 | 18 | 37 | 35 | 108 |
| Infections | D007239 | EFO_0000544 | — | 2 | 10 | 16 | 38 | 23 | 85 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 6 | 13 | 19 | 23 | 29 | 84 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 14 | 8 | 10 | 39 | 9 | 78 |
| Syndrome | D013577 | — | — | 4 | 7 | 9 | 16 | 33 | 66 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 3 | 19 | 22 | 15 | 10 | 63 |
| Healthy volunteers/patients | — | — | — | 34 | 2 | 3 | 2 | 20 | 61 |
| Acute kidney injury | D058186 | — | N17 | 2 | — | 5 | 5 | 34 | 46 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 7 | 6 | 10 | 9 | 11 | 39 |
Show 251 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 10 | 32 | 22 | — | 3 | 59 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 11 | 18 | 9 | — | — | 31 |
| Adenocarcinoma | D000230 | — | — | 9 | 11 | 9 | — | — | 27 |
| Squamous cell carcinoma | D002294 | — | — | 8 | 14 | 9 | — | — | 26 |
| Multiple myeloma | D009101 | — | C90.0 | 10 | 16 | 2 | — | 3 | 26 |
| Lung neoplasms | D008175 | — | C34.90 | 4 | 13 | 7 | — | 2 | 24 |
| Covid-19 | D000086382 | — | U07.1 | 3 | 9 | 6 | — | 12 | 24 |
| Hypogonadism | D007006 | — | E23.0 | 3 | 11 | 7 | — | 2 | 23 |
| Uterine cervical neoplasms | D002583 | — | — | 8 | 3 | 7 | — | 2 | 19 |
| Adenosquamous carcinoma | D018196 | — | — | 6 | 5 | 6 | — | — | 16 |
Show 249 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cough | D003371 | — | R05 | — | 1 | — | — | 9 | 10 |
| Central nervous system neoplasms | D016543 | — | — | 2 | 5 | — | — | 1 | 8 |
| Motor activity | D009043 | EFO_0003940 | — | 1 | 1 | — | — | 5 | 7 |
| Asphyxia neonatorum | D001238 | EFO_1000824 | P84 | 3 | 3 | — | — | 1 | 7 |
| Nervous system neoplasms | D009423 | — | — | 1 | 4 | — | — | 1 | 6 |
| Small cell lung carcinoma | D055752 | — | — | 3 | 4 | — | — | — | 6 |
| Hemostatic disorders | D020141 | — | — | 1 | 1 | — | — | 5 | 6 |
| Hypercholesterolemia | D006937 | — | — | 1 | 1 | — | — | 3 | 5 |
| Alopecia | D000505 | — | L64 | 1 | 1 | — | — | 3 | 5 |
| Glioma | D005910 | EFO_0000520 | — | — | 3 | — | — | 1 | 4 |
Show 182 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy rate | D018873 | — | — | 1 | — | — | — | 3 | 4 |
| Biological availability | D001682 | — | — | 1 | — | — | — | 3 | 4 |
| Fistula | D005402 | — | — | 1 | — | — | — | 2 | 3 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | 2 | — | — | — | 1 | 3 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | 2 | — | — | — | 1 | 3 |
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | 2 | — | — | — | — | 2 |
| Pure autonomic failure | D054970 | — | — | 1 | — | — | — | 1 | 2 |
| Ovarian hyperstimulation syndrome | D016471 | — | — | 1 | — | — | — | 1 | 2 |
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | 1 | — | — | — | 1 | 2 |
| Intraabdominal infections | D059413 | — | — | 1 | — | — | — | 1 | 2 |
Show 64 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatic insufficiency | D048550 | — | — | — | — | — | — | 6 | 6 |
| Chronic cough | D000096822 | — | R05.3 | — | — | — | — | 5 | 5 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | — | — | — | 5 | 5 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 4 | 4 |
| Nausea | D009325 | — | R11.0 | — | — | — | — | 3 | 3 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | — | 3 | 3 |
| Hyperthermia | D000084462 | — | — | — | — | — | — | 3 | 3 |
| Hemophilia b | D002836 | — | D67 | — | — | — | — | 3 | 3 |
| Rare diseases | D035583 | — | — | — | — | — | — | 3 | 3 |
| Weight loss | D015431 | — | — | — | — | — | — | 3 | 3 |
Show 295 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Citric acid |
| INN | dimpylate |
| Description | Idkit:hp (citric acid) is a small molecule pharmaceutical. Citric acid was first approved as Idkit:hp on 2002-12-17. It is used to treat renal tubular acidosis and urination disorders in the USA. It is known to target polycystic kidney disease 2-like 1 protein, transient receptor potential cation channel subfamily V member 4, and nectin-1. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)CC(O)(CC(=O)O)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 77-92-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1261 |
| ChEBI ID | 30769 |
| PubChem CID | 311 |
| DrugBank | DB04272 |
| UNII ID | XF417D3PSL (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PKD2L1
PKD2L1
NECTIN1
NECTIN1
Organism
Homo sapiens
Gene name
PKD2L1
Gene synonyms
PKD2L, PKDL, TRPP3
NCBI Gene ID
Protein name
polycystin-2-like protein 1
Protein synonyms
Polycystic kidney disease 2-like 1 protein, Polycystin-2 homolog, polycystin-2L1, Polycystin-L, Polycystin-L1, transient receptor potential cation channel, subfamily P, member 3
Uniprot ID
Mouse ortholog
Pkd2l1 (329064)
polycystin-2-like protein 1; polycystic kidney disease 2-like 1 protein (Q80ZH4)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Miplyffa – Zevra Therapeutics
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Sildenafil – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Lazanda – Assertio Therapeutics
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Viagra – Viatris
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Viagra – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Phexxi – Evofem Biosciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Revatio – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Auryxia – Keryx Biopharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Citric acid
+
Citric acid monohydrate
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 442,329 documents
View more details
Safety
Black-box Warning
Black-box warning for: Abstral, Citranatal, Citranatal assure, Citranatal essence, Citranatal harmony, Citranatal harmony 2.1, Citranatal harmony 3.0, Citranatal medley, Fareston, Fentanyl buccal, Fentanyl citrate, Hepzato kit, Lazanda, Melphalan hydrochloride, Soltamox, Sufentanil citrate, Tamoxifen citrate, Toremifene citrate, Transmucosal fentanyl citrate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
48,741 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use